About Applied Therapeutics
Applied Therapeutics is a publicly listed company based in New York (United States) founded in 2015, and was acquired by Cycle Pharma in December 2025. Drugs for metabolic and cardiovascular diseases are developed. Applied Therapeutics has raised $65.16 million across 7 funding rounds from investors including ARE, Cycle Pharma and Syno Capital. The company has 35 employees. Applied Therapeutics offers products and services including Govorestat and AT-001. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its legal entity is Applied Therapeutics, Inc. Its competitors include Tenaya Therapeutics, Cellino and MyoKardia; 3 of its 3 listed competitors have raised funding.
Company details
Applied Therapeutics was founded in 2015 and is headquartered in New York, United States. Focus is placed on the development of novel drugs targeting metabolic and cardiovascular diseases within the biotechnology sector. Proprietary technology, licensed from Dr. Donald Landrys laboratory at Columbia University, is applied to enzymes previously linked to these conditions but unsuccessful in prior therapies. Operations center on advancing these targets toward clinical applications.
- Headquarters New York, United States
- Employees 35
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website appliedtherapeutics.com
- Social LinkedIn X Facebook
- Acquired by Cycle Pharma (Dec 2025)
- Legal Name Applied Therapeutics, Inc.
- Annual Revenue$455 K (USD)-95.45as on Dec 31, 2024
- Net Profit-$105.62 M (USD)11.81as on Dec 31, 2024
- EBITDA-$103.87 M (USD)-61.84as on Dec 31, 2024
- Total Equity Funding$65.16M (USD)
in 7 rounds
- Latest Funding Round$100M (USD), Post-IPO
Feb 2024
- InvestorsARE
& 4 more
- Employee Count35
- Acquired byCycle Pharma
(Dec 2025)
Products & Services of Applied Therapeutics
Applied Therapeutics offers a comprehensive portfolio of products and services, including Govorestat and AT-001.
Drug targeting rare metabolic disorders for patient treatment.
Potential therapy for rare conditions in clinical development.
Funding Insights of Applied Therapeutics
Applied Therapeutics has successfully raised a total of $65.16M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65.16M
- Total Rounds 7
- Last Round Post-IPO — $100M
- First Round $7M
(Feb 2017)
- Investors Count 4
All 7 funding rounds of Applied Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $100M | Post-IPO | – | – | – |
| May 2023 | $30M | Post-IPO | – | – | – |
| Nov 2019 | $20.01M | Post-IPO | – | – | – |
| Feb 2019 | $25M | Series B | – | – | – |
| Nov 2018 | $27.16M | Series B | – | – | – |
| Feb 2018 | $6M | Series A | – | – | – |
| Feb 2017 | $7M | Series A | – | Alexandria |
5 investors in total: 5 institutional.
Investors in Applied Therapeutics
Applied Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Cycle Pharma and Syno Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Syno Capital is focused on healthcare investment and innovation. | 2015 | synocapital.com | New York, United States | |
US private equity investments are managed by E Squared Capital. | esquaredcapital.com | Great Neck, United States | ||
| etpglobalfund.tcc.mode | ||||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Small molecule drugs are reformulated and repurposed for orphan indications. | 2012 | cyclepharma.com | Cambridge, United Kingdom |
Investor details for Applied Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Applied Therapeutics
32 people are tracked at Applied Therapeutics (16 in leadership, 11 in board & advisors, 5 in team); the tracked headcount is 35.
| Name | Role | Group |
|---|---|---|
Sariah R. Persaud M.D. Ccrc | Executive Director, Clinical Operations | Leadership |
Shoshana Shendelman | CEO & Founder | Leadership |
Sally Lam | Executive Director Marketing | Leadership |
Gene McCarty | Sr. Director Market Access And Reimbursement | Leadership |
Ray Coggins | Vice President, Head of Marketing | Leadership |
Riccardo Perfetti | CMO | Leadership |
Mandy Krumnow, PharmD, MBA | Vice President Medical Affairs | Leadership |
Andrew Wasmuth | Vice President of Chemistry, Manufacturing and Formulation | Leadership |
Dale Hooks | Chief Commercial Officer | Leadership |
Evan Bailey | Chief Medical Officer | Leadership |
Dottie C. | Executive Vice President Patient Advocacy And Government Affairs | Leadership |
Darren Johnson | Vice President Of Commercial Operations | Leadership |
April Wiggins | Sr Director Of Market Insights | Leadership |
Jason Bey | Senior Director Of Market Insights | Leadership |
Liz Scott | Vice President Of Sales | Leadership |
Alex Tabraue | Director Of Market Access | Leadership |
Teena Lerner | Director | Board & advisors |
Donald Landry | Chair, Scientific Advisory Board | Board & advisors |
Lawrence Steinman | Scientific Advisor | Board & advisors |
Stacy Kanter | Director | Board & advisors |
12 more people are available in the full profile.
Complete people profiles for Applied Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Applied Therapeutics
Applied Therapeutics is a publicly listed company on the NASDAQ with ticker symbol APLT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 May 2019
- Listed onNASDAQ: APLT
- Listed entityApplied Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS03828A1016
- Share price$0.10 (+0.19% on the day) · 2026-02-04
- Market capitalisation$14.9M
- EPS (diluted, trailing year)$-0.10
- Volume (last session)2,704,732
- Analyst consensusNeutral
Financials of Applied Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $455,000 | -$105.6M | -$103.9M |
| 2023 | $10.0M | -$119.8M | -$64.2M |
| 2022 | -$82.5M | -$82.5M | |
| 2021 | -$105.6M | -$105.2M | |
| 2020 | -$94.0M | -$94.1M |
Detailed financial statements for Applied Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Applied Therapeutics
5 dated milestones of Applied Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Applied Therapeutics is founded.
- Funding First funding round of $7.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $100.0M.
- Exit Acquired by Cycle Pharma.
Competitors of Applied Therapeutics
Applied Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Tenaya Therapeutics, Cellino and MyoKardia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. |
Detailed competitors of Applied Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Applied Therapeutics
The website of Applied Therapeutics (appliedtherapeutics.com) receives about 6.2K visits a month and ranks #1,771,734 among all websites worldwide, #2,406 in Biotechnology and Pharmaceuticals.
- Monthly visits6.2K
▼ 55.9% vs previous month
- Unique visitors6K
per month
- Global rank#1,771,734
among all websites
- Category rank#2,406
Health · Biotechnology and Pharmaceuticals
- Bounce rate48%
- Pages per visit1.8
- Average visit1 min 16 sec
- DevicesDesktop 15% · Mobile 85%
Websites whose visitors overlap most with Applied Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cmtrf.org | 100% | #1,823,718 | View details | ||
cmtausa.org | cmtausa.org | 69% | #1,127,172 | – | |
| glycomine.com | 34% | 2.3K | #7,618,656 | View details |
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Applied Therapeutics (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Applied Therapeutics
Complete news archive for Applied Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Applied Therapeutics
Applied Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Applied Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Applied Therapeutics is a funded company, having raised a total of $65.16M across 7 funding rounds to date. The company's 1st funding round was a Series A of $7M, raised on Feb 2017.
Applied Therapeutics has 35 employees.
Annual revenue of Applied Therapeutics is $455K as on Dec 31, 2024.
Applied Therapeutics was founded in 2015 and is headquartered in New York, United States. Focus is placed on the development of novel drugs targeting metabolic and cardiovascular diseases within the biotechnology sector. Proprietary technology, licensed from Dr. Donald Landrys laboratory at Columbia University, is applied to enzymes previously linked to these conditions but unsuccessful in prior therapies. Operations center on advancing these targets toward clinical applications.
Applied Therapeutics's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
Applied Therapeutics offers Govorestat and AT-001.
Yes, Applied Therapeutics is publicly traded on NASDAQ under the ticker symbol APLT.
Applied Therapeutics has 5 investors. Key investors include ARE, Cycle Pharma, Syno Capital, E Squared Capital, and ETP Global Fund.
Applied Therapeutics operates through Applied Therapeutics, Inc..
Yes. Applied Therapeutics was acquired by Cycle Pharma in December 2025.